Free Trial
NASDAQ:BMRA

Biomerica (BMRA) Stock Price, News & Analysis

Biomerica logo
$3.61 +0.01 (+0.28%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$3.58 -0.03 (-0.97%)
As of 05/2/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Biomerica Stock (NASDAQ:BMRA)

Key Stats

Today's Range
$3.55
$3.73
50-Day Range
$3.35
$6.07
52-Week Range
$1.93
$10.16
Volume
7,068 shs
Average Volume
276,277 shs
Market Capitalization
$9.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Biomerica Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
26th Percentile Overall Score

BMRA MarketRank™: 

Biomerica scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Biomerica.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Biomerica is -10.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Biomerica is -10.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Biomerica has a P/B Ratio of 9.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.72% of the float of Biomerica has been sold short.
  • Short Interest Ratio / Days to Cover

    Biomerica has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Biomerica has recently decreased by 91.18%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Biomerica does not currently pay a dividend.

  • Dividend Growth

    Biomerica does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.72% of the float of Biomerica has been sold short.
  • Short Interest Ratio / Days to Cover

    Biomerica has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Biomerica has recently decreased by 91.18%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Biomerica has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Biomerica this week, compared to 0 articles on an average week.
  • Search Interest

    8 people have searched for BMRA on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Biomerica to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Biomerica insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    15.00% of the stock of Biomerica is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 22.28% of the stock of Biomerica is held by institutions.

  • Read more about Biomerica's insider trading history.
Receive BMRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter.

BMRA Stock News Headlines

Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
Biomerica, Inc.: Biomerica Announces Reverse Stock Split
Biomerica Inc trading halted, news pending
See More Headlines

BMRA Stock Analysis - Frequently Asked Questions

Biomerica's stock was trading at $2.4008 at the beginning of 2025. Since then, BMRA stock has increased by 50.4% and is now trading at $3.61.
View the best growth stocks for 2025 here
.

Biomerica, Inc. (NASDAQ:BMRA) posted its quarterly earnings results on Monday, April, 14th. The company reported ($0.48) earnings per share (EPS) for the quarter. The firm had revenue of $1.12 million for the quarter. Biomerica had a negative trailing twelve-month return on equity of 90.19% and a negative net margin of 100.52%.

Shares of Biomerica reverse split on the morning of Monday, April 21st 2025. The 1-8 reverse split was announced on Wednesday, April 16th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 18th 2025. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Shares of BMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biomerica investors own include Pfizer (PFE), Gilead Sciences (GILD), AT&T (T), NIO (NIO), Exxon Mobil (XOM), Avino Silver & Gold Mines (ASM) and Avino Silver & Gold Mines (ASM).

Company Calendar

Last Earnings
4/14/2025
Today
5/03/2025
Fiscal Year End
5/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BMRA
Employees
60
Year Founded
1971

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,980,000.00
Net Margins
-100.52%
Pretax Margin
-100.31%

Debt

Sales & Book Value

Annual Sales
$5.68 million
Price / Cash Flow
N/A
Book Value
$0.39 per share
Price / Book
9.26

Miscellaneous

Free Float
15,586,000
Market Cap
$9.19 million
Optionable
Optionable
Beta
0.37

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:BMRA) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners